ReviewGastroenterology2011
Future therapeutic approaches for inflammatory bowel diseases.
Review in Gastroenterology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Review
- Cytoskeletal Organization and Cell Polarity in the Pathogenesis of Crohn's Disease.Clinical reviews in allergy & immunology · 2021Review
- Dual-Functionalized MSCs that Express CX3CR1 and IL-25 Exhibit Enhanced Therapeutic Effects on Inflammatory Bowel Disease.Molecular therapy : the journal of the American Society of Gene Therapy · 2020Article
- Receptor for Advanced Glycation End Products Acts as a Fuel to Colorectal Cancer Development.Frontiers in oncology · 2020Review
- Does Medical Acceleration Improve Outcomes in Ulcerative Colitis Patients Who Are in Clinical Remission but Have Endoscopic Inflammation?Digestive diseases and sciences · 2018Article
- Metabolic control of T cell immune response through glycans in inflammatory bowel disease.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Bioengineering Bacterially Derived Immunomodulants: A Therapeutic Approach to Inflammatory Bowel Disease.ACS nano · 2017Article
- Suppression Colitis and Colitis-Associated Colon Cancer by Anti-S100a9 Antibody in Mice.Frontiers in immunology · 2017Article
- Contribution of the IL-17/IL-23 axis to the pathogenesis of inflammatory bowel disease.World journal of gastroenterology · 2015Review
- Butein effects in colitis and interleukin-6/signal transducer and activator of transcription 3 expression.World journal of gastroenterology · 2015Article
- Ginsenoside Rh2 alleviates dextran sulfate sodium-induced colitis via augmenting TGFβ signaling.Molecular biology reports · 2014Article
- Oral treatment with SEW2871, a sphingosine-1-phosphate type 1 receptor agonist, ameliorates experimental colitis in interleukin-10 gene deficient mice.Clinical and experimental immunology · 2014Article
- Propionyl-L-Carnitine is Efficacious in Ulcerative Colitis Through its Action on the Immune Function and Microvasculature.Clinical and translational gastroenterology · 2014Article
- Exome sequencing identifies DLG1 as a novel gene for potential susceptibility to Crohn's disease in a Chinese family study.PloS one · 2014Article
- Induced and natural regulatory T cells in the development of inflammatory bowel disease.Inflammatory bowel diseases · 2013Review
- Article
- Working out mechanisms of controlled/physiologic inflammation in the GI tract.Immunologic research · 2012Review
- Prevention of colitis-associated cancer: natural compounds that target the IL-6 soluble receptor.Anti-cancer agents in medicinal chemistry · 2012Review
- Potential prospects of nanomedicine for targeted therapeutics in inflammatory bowel diseases.World journal of gastroenterology · 2012Review
- Butyrate suppresses colonic inflammation through HDAC1-dependent Fas upregulation and Fas-mediated apoptosis of T cells.American journal of physiology. Gastrointestinal and liver physiology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
In this review, we speculate about future therapeutic approaches for inflammatory bowel diseases (IBDs), focusing on the need for better preclinical and clinical models and approaches beyond small molecules and systemically administered biologics. We offer ideas to change clinical trial programs and to use immunologic and genetic biomarkers to personalize medicine. We attempt to reconcile past therapeutic successes and failures to improve future approaches. Some of our ideas might be provocative, but we hope that the examples we provide will stimulate discussion about what will advance the field of IBD therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.